Cyclodextrin-Nanosponge-Loaded Cyclo-Oxygenase-2 Inhibitor-Based Topical Gel for Treatment of Psoriatic Arthritis: Formulation Design, Development, and <i>In vitro</i> Evaluations
<b>Background:</b> Psoriatic arthritis (PsA), a chronic inflammatory disease, mainly affects the joints, with approximately 30% of psoriasis patients eventually developing PsA. Characterized by both innate and adaptive immune responses, PsA poses significant challenges for effective trea...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/17/12/1598 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850037437157343232 |
|---|---|
| author | Umme Hani Sharanya Paramshetti Mohit Angolkar Wajan Khalid Alqathanin Reema Saeed Alghaseb Saja Mohammed Al Asmari Alhanouf A. Alsaab Farhat Fatima Riyaz Ali M. Osmani Ravi Gundawar |
| author_facet | Umme Hani Sharanya Paramshetti Mohit Angolkar Wajan Khalid Alqathanin Reema Saeed Alghaseb Saja Mohammed Al Asmari Alhanouf A. Alsaab Farhat Fatima Riyaz Ali M. Osmani Ravi Gundawar |
| author_sort | Umme Hani |
| collection | DOAJ |
| description | <b>Background:</b> Psoriatic arthritis (PsA), a chronic inflammatory disease, mainly affects the joints, with approximately 30% of psoriasis patients eventually developing PsA. Characterized by both innate and adaptive immune responses, PsA poses significant challenges for effective treatment. Recent advances in drug delivery systems have sparked interest in developing novel formulations to improve therapeutic outcomes. The current research focuses on the development and evaluation of a nanosponge-loaded, cyclo-oxygenase-2 (COX-2) inhibitor-based topical gel for the treatment of PsA. <b>Methods:</b> Nanosponges (NSs) were prepared by using beta-cyclodextrin as a polymer and dimethyl carbonate (DMC) as a crosslinker by melting, and gels were prepared by employing carbopol and badam gum as polymers. <b>Results:</b> Solubility studies confirmed that the prepared nanosponges were highly soluble. FT-IR studies confirmed the formation of hydrogen bonds between lumiracoxib and beta-cyclodextrin. SEM confirmed that the prepared formulations were roughly spherical and porous in nature. The average particle size was 190.5 ± 0.02 nm, with a zeta potential of −18.9 mv. XRD studies showed that the crystallinity of lumiracoxib decreased after encapsulation, which helped to increase its solubility. The optimized nanosponges (NS2) were incorporated in an optimized gel (FG10) to formulate a nanosponge-loaded topical gel. The optimized gel formulation exhibited a homogeneous consistency, with a pH of 6.8 and a viscosity of 1.15 PaS, indicating its suitability for topical application and stability. The <i>in vitro</i> diffusion studies for the topical gel showed drug release of 82.32% in 24 h. The optimized formulation demonstrated significant antipsoriatic activity, as confirmed through cytotoxicity studies conducted on HaCaT cells. <b>Conclusions:</b> On the basis of the findings, it can be concluded that the prepared nanosponge-loaded topical gel formulation presents a promising solution for the effective management of PsA, offering enhanced drug solubility, sustained release, and improved therapeutic potential. |
| format | Article |
| id | doaj-art-c64da751b6214029968c833c2bbddd93 |
| institution | DOAJ |
| issn | 1424-8247 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-c64da751b6214029968c833c2bbddd932025-08-20T02:56:51ZengMDPI AGPharmaceuticals1424-82472024-11-011712159810.3390/ph17121598Cyclodextrin-Nanosponge-Loaded Cyclo-Oxygenase-2 Inhibitor-Based Topical Gel for Treatment of Psoriatic Arthritis: Formulation Design, Development, and <i>In vitro</i> EvaluationsUmme Hani0Sharanya Paramshetti1Mohit Angolkar2Wajan Khalid Alqathanin3Reema Saeed Alghaseb4Saja Mohammed Al Asmari5Alhanouf A. Alsaab6Farhat Fatima7Riyaz Ali M. Osmani8Ravi Gundawar9Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62529, Saudi ArabiaDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSS AHER), Mysuru 570015, Karnataka, IndiaDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSS AHER), Mysuru 570015, Karnataka, IndiaDepartment of Doctor of Pharmacy, College of Pharmacy, King Khalid University, Abha 62529, Saudi ArabiaDepartment of Doctor of Pharmacy, College of Pharmacy, King Khalid University, Abha 62529, Saudi ArabiaDepartment of Doctor of Pharmacy, College of Pharmacy, King Khalid University, Abha 62529, Saudi ArabiaPharmacist at Abha International Private Hospital, Abha 62521, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi ArabiaDepartment of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSS AHER), Mysuru 570015, Karnataka, IndiaDepartment of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India<b>Background:</b> Psoriatic arthritis (PsA), a chronic inflammatory disease, mainly affects the joints, with approximately 30% of psoriasis patients eventually developing PsA. Characterized by both innate and adaptive immune responses, PsA poses significant challenges for effective treatment. Recent advances in drug delivery systems have sparked interest in developing novel formulations to improve therapeutic outcomes. The current research focuses on the development and evaluation of a nanosponge-loaded, cyclo-oxygenase-2 (COX-2) inhibitor-based topical gel for the treatment of PsA. <b>Methods:</b> Nanosponges (NSs) were prepared by using beta-cyclodextrin as a polymer and dimethyl carbonate (DMC) as a crosslinker by melting, and gels were prepared by employing carbopol and badam gum as polymers. <b>Results:</b> Solubility studies confirmed that the prepared nanosponges were highly soluble. FT-IR studies confirmed the formation of hydrogen bonds between lumiracoxib and beta-cyclodextrin. SEM confirmed that the prepared formulations were roughly spherical and porous in nature. The average particle size was 190.5 ± 0.02 nm, with a zeta potential of −18.9 mv. XRD studies showed that the crystallinity of lumiracoxib decreased after encapsulation, which helped to increase its solubility. The optimized nanosponges (NS2) were incorporated in an optimized gel (FG10) to formulate a nanosponge-loaded topical gel. The optimized gel formulation exhibited a homogeneous consistency, with a pH of 6.8 and a viscosity of 1.15 PaS, indicating its suitability for topical application and stability. The <i>in vitro</i> diffusion studies for the topical gel showed drug release of 82.32% in 24 h. The optimized formulation demonstrated significant antipsoriatic activity, as confirmed through cytotoxicity studies conducted on HaCaT cells. <b>Conclusions:</b> On the basis of the findings, it can be concluded that the prepared nanosponge-loaded topical gel formulation presents a promising solution for the effective management of PsA, offering enhanced drug solubility, sustained release, and improved therapeutic potential.https://www.mdpi.com/1424-8247/17/12/1598cyclodextrinnanospongesolubilitycontrolled releasesolubility enhancementpsoriatic arthritis |
| spellingShingle | Umme Hani Sharanya Paramshetti Mohit Angolkar Wajan Khalid Alqathanin Reema Saeed Alghaseb Saja Mohammed Al Asmari Alhanouf A. Alsaab Farhat Fatima Riyaz Ali M. Osmani Ravi Gundawar Cyclodextrin-Nanosponge-Loaded Cyclo-Oxygenase-2 Inhibitor-Based Topical Gel for Treatment of Psoriatic Arthritis: Formulation Design, Development, and <i>In vitro</i> Evaluations Pharmaceuticals cyclodextrin nanosponge solubility controlled release solubility enhancement psoriatic arthritis |
| title | Cyclodextrin-Nanosponge-Loaded Cyclo-Oxygenase-2 Inhibitor-Based Topical Gel for Treatment of Psoriatic Arthritis: Formulation Design, Development, and <i>In vitro</i> Evaluations |
| title_full | Cyclodextrin-Nanosponge-Loaded Cyclo-Oxygenase-2 Inhibitor-Based Topical Gel for Treatment of Psoriatic Arthritis: Formulation Design, Development, and <i>In vitro</i> Evaluations |
| title_fullStr | Cyclodextrin-Nanosponge-Loaded Cyclo-Oxygenase-2 Inhibitor-Based Topical Gel for Treatment of Psoriatic Arthritis: Formulation Design, Development, and <i>In vitro</i> Evaluations |
| title_full_unstemmed | Cyclodextrin-Nanosponge-Loaded Cyclo-Oxygenase-2 Inhibitor-Based Topical Gel for Treatment of Psoriatic Arthritis: Formulation Design, Development, and <i>In vitro</i> Evaluations |
| title_short | Cyclodextrin-Nanosponge-Loaded Cyclo-Oxygenase-2 Inhibitor-Based Topical Gel for Treatment of Psoriatic Arthritis: Formulation Design, Development, and <i>In vitro</i> Evaluations |
| title_sort | cyclodextrin nanosponge loaded cyclo oxygenase 2 inhibitor based topical gel for treatment of psoriatic arthritis formulation design development and i in vitro i evaluations |
| topic | cyclodextrin nanosponge solubility controlled release solubility enhancement psoriatic arthritis |
| url | https://www.mdpi.com/1424-8247/17/12/1598 |
| work_keys_str_mv | AT ummehani cyclodextrinnanospongeloadedcyclooxygenase2inhibitorbasedtopicalgelfortreatmentofpsoriaticarthritisformulationdesigndevelopmentandiinvitroievaluations AT sharanyaparamshetti cyclodextrinnanospongeloadedcyclooxygenase2inhibitorbasedtopicalgelfortreatmentofpsoriaticarthritisformulationdesigndevelopmentandiinvitroievaluations AT mohitangolkar cyclodextrinnanospongeloadedcyclooxygenase2inhibitorbasedtopicalgelfortreatmentofpsoriaticarthritisformulationdesigndevelopmentandiinvitroievaluations AT wajankhalidalqathanin cyclodextrinnanospongeloadedcyclooxygenase2inhibitorbasedtopicalgelfortreatmentofpsoriaticarthritisformulationdesigndevelopmentandiinvitroievaluations AT reemasaeedalghaseb cyclodextrinnanospongeloadedcyclooxygenase2inhibitorbasedtopicalgelfortreatmentofpsoriaticarthritisformulationdesigndevelopmentandiinvitroievaluations AT sajamohammedalasmari cyclodextrinnanospongeloadedcyclooxygenase2inhibitorbasedtopicalgelfortreatmentofpsoriaticarthritisformulationdesigndevelopmentandiinvitroievaluations AT alhanoufaalsaab cyclodextrinnanospongeloadedcyclooxygenase2inhibitorbasedtopicalgelfortreatmentofpsoriaticarthritisformulationdesigndevelopmentandiinvitroievaluations AT farhatfatima cyclodextrinnanospongeloadedcyclooxygenase2inhibitorbasedtopicalgelfortreatmentofpsoriaticarthritisformulationdesigndevelopmentandiinvitroievaluations AT riyazalimosmani cyclodextrinnanospongeloadedcyclooxygenase2inhibitorbasedtopicalgelfortreatmentofpsoriaticarthritisformulationdesigndevelopmentandiinvitroievaluations AT ravigundawar cyclodextrinnanospongeloadedcyclooxygenase2inhibitorbasedtopicalgelfortreatmentofpsoriaticarthritisformulationdesigndevelopmentandiinvitroievaluations |